Monoclonal B-cell lymphocytosis in individuals from sporadic (non-familial) chronic lymphocytic leukemia families persists over time, but does not progress to chronic B-cell lymphoproliferative diseases  by Matos, Daniel Mazza et al.
rev bras hematol hemoter. 2 0 1 5;3  7(5):292–295
www.rbhh.org
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
Original article
Monoclonal  B-cell  lymphocytosis  in  individuals
from sporadic  (non-familial)  chronic  lymphocytic
leukemia families  persists  over  time,  but  does  not
progress to  chronic  B-cell  lymphoproliferative
diseases
Daniel Mazza Matos ∗, Felipe Magalhães Furtado, Roberto Passetto Falcão
Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 5 March 2015
Accepted 8 May 2015
Available online 30 June 2015
Keywords:
Monoclonal B-cell lymphocytosis
Chronic lymphocytic leukemia
Flow cytometry
B cells
First-degree relatives
a  b  s  t  r  a  c  t
Background: Monoclonal B-cell lymphocytosis is classiﬁed as ‘high-count or clinical’ mono-
clonal B-cell lymphocytosis and ‘low-count or population’ monoclonal B-cell lymphocytosis.
Previously, 167 ﬁrst-degree relatives pertaining to sporadic (non-familial) chronic lym-
phocytic leukemia families were studied and the presence of seven monoclonal B-cell
lymphocytosis individuals was reported.
Objective: The aim of this report is to describe the outcomes of ﬁve of the original monoclonal
B-cell lymphocytosis individuals.
Methods: Flow cytometry analysis was performed on mononuclear cells previously isolated
from peripheral blood samples. A strategy of sequential gating designed to identify the
population of CD19+/CD5+ B-lymphocytes was used and, subsequently, the monoclonal B-
cell  lymphocytosis cells were characterized by the CD20weak/CD79bweak/negative phenotype.
Results: The monoclonal B-cell lymphocytosis clone showed consistent stability over time
with  little variations in size. After a median follow-up of 7.6 years, none of the ﬁve mono-
clonal B-cell lymphocytosis individuals progressed to chronic lymphocytic leukemia or other
B-cell lymphoproliferative disease.
Conclusions: The data of this study suggest that chronic lymphocytic leukemia-like mon-
oclonal B-cell lymphocytosis detected in the context of sporadic chronic lymphocytic
leukemia families is not prone to clinical evolution and could be just a sign of immune
senescence.
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onoclonal B-cell lymphocytosis (MBL) is deﬁned as the pres-
nce of low levels of circulating abnormal B-cells in the
eripheral blood of apparently healthy subjects, identiﬁed
y means of immunophenotypic characterization performed
y ﬂow cytometry. Phenotypically, MBL  presents as chronic
ymphocytic leukemia (CLL)-like MBL, atypical MBL and
on-CLL MBL. Moreover, MBL  is classiﬁed into two cate-
ories: ‘high-count or clinical MBL’,  in which individuals have
bsolute lymphocytosis, but with B-cell counts lower than
 × 109 cells/L and ‘low-count or population MBL’  cases found
y screening individuals without lymphocytosis.1
Notwithstanding the same phenotype, high-count and
ow-count CLL-like MBL  are biologically different entities
egarding speciﬁc immunoglobulin heavy chain variable
IGHV) genes, the size of B-cell compartment, the prevalence
n general population and, mainly, the risk of evolution to CLL
equiring treatment. Thus, high-count CLL-like MBL  is really a
re-malignant condition characterized by the risk of progres-
ion to overt CLL in 1–5% of cases per year.2 On the other hand,
he main study on low-count CLL-like MBL  published so far3
howed that the condition persists in approximately 90% of
ubjects, with some cases regressing over time.
Previously, a total of 167 ﬁrst-degree relatives of sporadic
non-familial) CLL patients pertaining to 42 families (sporadic
LL families) were studied by the current authors and the
resence of seven MBL  individuals in this particular epidemi-
logical setting was reported.4 Thus, taking advantage of the
revious ﬁndings, this study describes the outcomes and the
ize of B-cell clones in this very particular group of subjects.
ethods
he following criteria were used to diagnose MBL: (a) a disease-
peciﬁc immunophenotype or an overall kappa/lambda ratio
3:1 or <0.3:1, (b) stable monoclonal B-cell population over
 three-month period, (c) absence of lymphadenopathy,
rganomegaly, and autoimmune or infectious diseases, and
d) B-lymphocyte counts < 5 × 109/L.5
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Flow cytometry studies were performed as previously
described.4 Brieﬂy, mononuclear cells were isolated from
peripheral blood samples by Ficoll Hypaque (Sigma–Aldrich, St
Louis, MO, USA) density gradient centrifugation. The diluted
blood sample (1:1) was carefully layered on Ficoll Hypaque
(5 mL)  previously added to a centrifuge tube. The sample was
centrifuged at 400 × g for 30–40 min. Using a clean Pasteur
pipette, the mononuclear cells were transferred to a clean cen-
trifuge tube. The ﬁnal concentration was adjusted to 1.0 × 106
cells per tube. Antibodies for the following antigens were used:
CD5 (APC), CD19 (PerCP-Cy5.5), CD20 (FITC), CD79b (PE), anti-
(FITC), anti- (PE), polyclonal anti- (FITC), and polyclonal anti-
 (PE). All monoclonal antibodies were purchased from Becton
Dickinson (BD, San Jose, CA, USA) except polyclonal anti- and
anti- (Dako Denmark A/S, USA). All samples were analyzed
using a FACSCalibur ﬂow cytometer (BD, San Jose, CA, USA). A
total of 300,000 events per tube were acquired.
Flow cytometry analysis was performed as follows: after
the identiﬁcation of the whole lymphocyte population (R1
gate) the sequential gating strategy was designed to specif-
ically identify the population of CD19+/CD5+ B-lymphocytes
(R2 gate) and, subsequently, the MBL cells were character-
ized for the CD20weak/CD79bweak/negative phenotype (R3 gate)
(Figure 1). The percentage of MBL cells was calculated based
on the population of CD19+/CD5+ B-lymphocytes in peripheral
blood.
As previously described, MBL was detected in seven ﬁrst-
degree relatives from ﬁve families in a total of 167 subjects
studied.4 Five of these seven MBL individuals were followed
up. Two individuals refused clinical surveillance. The other
ﬁve individuals were followed up at Universidade de São Paulo
(USP) in Ribeirão Preto with annual medical consultations
including history, physical exam and complete blood count.
All MBL subjects had no lymphocytosis at diagnosis and were
initially classiﬁed as ‘low-count MBL’, although these individ-
uals did not come from the general population (see Discussion
section).Results
The clinical and laboratorial characteristics of the seven orig-
inally described MBL individuals are shown in Table 1. After
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Figure 2 – (A) Monoclonal B-cell lymphocytosis clone size
variation. (B) Percentage of monoclonal B-cell
lymphocytosis cells of each individual (P1, P2, P3, P4, P5)
over time.
a median follow-up of 7.6 years (range: 6.6–8.1 years) no
individual progressed to CLL or other chronic B-cell lympho-
proliferative disease, since all of them persisted with a B-cell
count lower than 5 × 109 cells/L.
The MBL clone showed consistent stability over time, with
little variations in size (Figure 2). It is worth noting that only
one patient (P1 – Figure 2) had a little increase of clone size. At
diagnosis in 2006, this individual presented with a monoclonal
population (/ = 0.08:1) characterized by an atypical MBL  phe-
notype (CD5+/CD20bright). At the last follow-up in 2014, ﬂow
cytometry analysis showed that the monoclonal + population
persisted without an expressive increase.
Discussion
CLL-like MBL is classiﬁed into two subgroups: ‘high-count or
clinical MBL’,  usually diagnosed in a clinical setting, and ‘low-
count or population MBL’, found by screening healthy individ-
uals in the general population.6 It is noteworthy that our group
of subjects, from an epidemiological perspective, does not per-
tain either to clinical or population MBL, because they came
from speciﬁc sporadic (non-familial) CLL families. However,
with regard to the size of the abnormal B-cell compartment,
our group is somehow related to low-count CLL-like MBL. The
results of this study recall those of Fazi et al.3 that showed
the persistency of low count CLL-like MBL  without clinical
progression, though their study was conducted in a different
population, i.e., healthy individuals diagnosed in an Italian
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ural valley community. Furthermore, the Leeds group reeval-
ated 42 MBL  cases diagnosed in hospital outpatients after a
edian follow-up of 4.3 years. The absolute lymphocyte count
as normal in 38/42, with 4/42 developing lymphocytosis, of
hich three were diagnosed with high-count CLL-like MBL.2
As stated by Ghia et al.,7 probably the most important ques-
ion concerning population MBL  is whether, given enough
ime, all these cases will become clinical MBL and, sub-
equently, every clinical MBL  will become overt CLL. This
uestion has yet more  relevance with regard to MBL  cases
iagnosed inside sporadic CLL families. In fact, the best epi-
emiological data conﬁrm genetic susceptibility to CLL, as
rst-degree relatives of CLL cases were found to be at sig-
iﬁcantly increased risk for CLL [relative risk (RR) = 7.5; 95%
onﬁdence interval (95% CI): 3.63–15.56].8 Thus, the data of this
tudy, though limited due to sample size, but with a median
ollow-up of 7.6 years, suggest that ‘sporadic CLL family-MBL’
s not prone to clinical evolution and that these abnormal B-
ell expansions could be just a sign of immune senescence.
hus, clonal expansions among some subsets of T cells, as
ommonly seen in the elderly, closely resemble CLL-like MBL
n healthy individuals, with the frequency of which being age-
elated.9,10
onclusions
LL-like MBL  detected in the context of sporadic CLL families
s apparently stable over time, similar to other low-count MBL
ases diagnosed in population-screening surveys. This entity
s probably not a pre-leukemic condition and could just be a
ignal of immune repertoire restrictions occurring with age in
ealthy individuals.onﬂicts  of  interest
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